SECURITIES AND EXCHANGE COMMISSION
                              WASHINGTON, DC 20549

                                    FORM 6-K

                        REPORT OF FOREIGN PRIVATE ISSUER
                      PURSUANT TO RULE 13a-16 OR 15d-16 OF
                       THE SECURITIES EXCHANGE ACT OF 1934



For the month of June 2001.




                                 CGI Group Inc.
                 (Translation of Registrant's Name Into English)



                           1130 Sherbrooke Street West
                                    5th Floor
                                Montreal, Quebec
                                 Canada H3A 2M8
                    (Address of Principal Executive Offices)



     (Indicate  by check mark whether the  registrant  files or will file annual
reports under cover of Form 20-F or Form 40-F.)

Form 20-F           Form 40-F   |X|



     (Indicate  by  check  mark  whether  the   registrant  by  furnishing   the
information contained in this form is also thereby furnishing the information to
the Commission  pursuant to Rule 12g3-2(b) under the Securities  Exchange Act of
1934.)

Yes         No   |X|


(If "Yes" is marked,  indicate below the file number  assigned to the registrant
in connection with Rule 12g3-2(b): 82-___.


Enclosure:  Press Release dated June 26, 2001

This Form 6-K shall be deemed  incorporated  by  reference  in the  Registrant's
Registration Statement on Form S-8, Reg. Nos. 333-9106 and 333-13350.



     PRESS RELEASE                                FOR IMMEDIATE PUBLICATION

    Caprion, Sun, Oracle Consulting and CGI Collaborate In Proteomics Effort

          Bioinformatics Platform to Deliver High-Performance Solution
                       for Acceleration of Drug Discovery

Montreal,  June 26,  2001 --  Caprion  Pharmaceuticals  Inc.,  a  drug-discovery
company  applying  proteomics  and cell  biology  expertise,  today  announced a
collaboration to develop and operate a highly scalable  bioinformatics  platform
for proteomic  disease  modeling as part of Caprion's  CellCarta  drug discovery
offering. Technologies,  hardware and software from Sun Microsystems and Oracle,
and systems integration  expertise from CGI will be combined with Caprion's cell
biology and mass spectrometry  techniques to analyze,  map and store the protein
differences between normal and diseased cells.

Caprion's  CellCarta  Solaris  platform,  will  include  servers,   storage  and
infrastructure  solutions  from Sun and  Oracle,  which will  enable  Caprion to
effectively   study   proteins   within   cells   by   creating    comprehensive
three-dimensional  maps of protein  location and orientation in their biological
context.  Caprion uses mass  spectrometers to digitize  cellular  information in
multiple  states,  identifying  and modeling  disease.  A data warehouse will be
designed and developed by Oracle Consulting.

Caprion hopes to accelerate the detection of  disease-related  proteins  through
the  creation  of a  specialized  data  centre.  This  centre,  expected  to  be
operational in September,  2001, will process up to 100 terabytes of information
per year and will  represent  one of the largest and fastest  dedicated  protein
analysis server banks in the world.

With the completion of a rough draft of the human genetic code,  researchers are
now  launching   large-scale  efforts  to  study  proteins,  a  field  known  as
proteomics.  Proteins carry information  within and between cells, and carry out
most of life's basic  processes.  Proteomics  is expected to lead to advances in
treating HIV, cancer and other diseases.

"We're very excited about this  platform,  because it brings the best  solutions
from  Sun  and   Oracle   which   will  speed   breakthroughs   in   identifying
disease-related  proteins,"  said Lloyd M. Segal,  president and chief executive
officer of Caprion Pharmaceuticals.  "Sun and Oracle's significant contributions
of  software  and  information  management  capabilities  are beyond that of any
proteomics company, and allow us to apply key knowledge from other industries to
meet our  challenges.  CGI's  ability to integrate  the entire  program made our
goals of data throughput possible in the limited time we have available."
                                                                      .../2





Press release - page 2


Sun  is  expected  to  invest  substantial   software   engineering   resources,
professional services, Enterprise-class servers, Sun StorEdge offerings, and the
Solaris Operating  Environment.  Sun is a leader in the UNIX(R) systems and open
storage market with a  comprehensive  set of network  storage  offerings for the
enterprise market.

"Sun's  highly  reliable,  scalable and  available  systems are already  helping
Caprion speed up the massive computational  processing required to analyze their
biological data," said Scott McNealy,  chairman and CEO, Sun Microsystems,  Inc.
"Sun  is  providing  a core  piece  of the  technology  that  is  enabling  this
proteomics  revolution.  With the  potential  for  analysis  of over one million
proteins in the human body,  Sun and Caprion are  harnessing  today's  computing
power to help transform the future of medicine."

In addition  to using the Oracle  database as the  software  foundation  for the
project, Oracle Consulting will design and develop the Pipeline data warehouse.

"Oracle is the most widely  distributed  database  platform in the biotechnology
and   pharmaceutical   industries,"  said  Bill  Bergen,   president  of  Oracle
Corporation  Canada Inc. "Its robust and scaleable products will provide Caprion
with a superior  platform to meet - and exceed - its goals and objectives in the
critically   important   areas  of  genetic   research,   proteomics   and  drug
development."

CGI will  provide  system  integration,  consultation,  project  management  and
development  for this  project.  CGI will  support and  maintain the data centre
operations for a period of five years.

"We are very  pleased  and  excited  about this  critical  undertaking.  We look
forward to the challenge of integrating seven major components that have to talk
to each other,  all within this very complex  structure.  The  challenges of the
architecture  are due to  Caprion's  ability  to  create  unprecedented  digital
resolution of cells," said Serge Godin, chairman, president and CEO of CGI.

About Caprion
Caprion  Pharmaceuticals  Inc. is a biotechnology  company applying proteomics -
the study of the nature and function of proteins - to  accelerate  the diagnosis
and treatment of disease.  Caprion's provides CellCarta  proteomics research for
major biopharmaceutical  companies to increase the speed and efficiency of early
stage drug discovery and to develop its own diagnostic and therapeutic products.
Caprion's current product development programs include the first blood screening
reagents for Mad Cow Disease and its human equivalent.  For more on Caprion, see
www.caprion.com.

About Sun Microsystems, Inc.
Since its inception in 1982, a singular  vision -- "The Network Is The Computer"
- -- has  propelled  Sun  Microsystems  to its  position as a leading  provider of
industrial-strength  hardware, software and services that power the Internet and
allow  companies  worldwide  to take  their  businesses  to the nth.  With $19.2
billion in annual  revenues,  Sun can be found in more than 170 countries and on
the World Wide Web at www.sun.com.
                                                                      .../3


Press release - page 3


About CGI
Founded in 1976, CGI is the  fifth-largest  independent  information  technology
services  firm in North  America,  based on its  headcount  of more than  10,000
professionals.  CGI's order backlog totals approximately US$5.3 billion (CDN$8.2
billion) and its revenue  run-rate is close to US$1 billion  (CDN$1.5  billion).
CGI provides  end-to-end IT services and business  solutions to 2,500 clients in
the United  States,  Canada and more than 20 countries  around the world.  CGI's
shares are listed on the NYSE  (GIB),  as well as on the TSE  (GIB.A).  They are
included in the Toronto  Stock  Exchange's  TSE 300 index as well as the S&P/TSE
Canadian Information Technology index. For more on CGI, see www.cgi.ca.


Trademarks
Sun, Sun Microsystems,  the Sun logo, Sun Enterprise,  Sun StorEdge, Solaris and
The Network Is The Computer  are  trademarks  or  registered  trademarks  of Sun
Microsystems  in the Unites  States and other  countries.  UNIX is a  registered
trademark in the United States and other countries, exclusively licensed through
X/Open   Company,   Ltd.   Caprion  and  CellCarta  are  trademarks  of  Caprion
Pharmaceuticals, Inc.

All statements in this press release that do not directly and exclusively relate
to historical facts constitute  "forward-looking  statements" within the meaning
of the  Private  Securities  Litigation  Reform  Act of 1995.  These  statements
represent CGI Group Inc.'s intentions, plans, expectations, and beliefs, and are
subject to risks, uncertainties, and other factors, of which many are beyond the
control of the  Company.  These  factors  could cause  actual  results to differ
materially from such forward-looking statements.

These  factors  include  and  are  not  restricted  to the  timing  and  size of
contracts, acquisitions and other corporate developments, the ability to attract
and retain  qualified  employees,  market  competition  in the  rapidly-evolving
information technology industry,  general economic and business conditions,  and
other risks  identified in  Management's  Discussion and Analysis  (MD&A) in CGI
Group Inc.'s  annual  report or Form 40F filed with the US Securities & Exchange
Commission  and the  Company's  Annual  Information  Form  filed  with  Canadian
securities  commissions.  All  of the  risk  factors  included  in  these  filed
documents  are  included  here by  reference.  CGI  disclaims  any  intention or
obligation  to update or revise  any  forward-looking  statements,  whether as a
result of new information, future events or otherwise.

                                      -30-

FOR MORE INFORMATION:

Lloyd M. Segal                Doron Aronson               Ronald White
Caprion Pharmaceuticals Inc.  Sun Microsystems, Inc.      CGI
(514) 940-3604                (408) 517-5529              (514) 841-3230
lsegal@caprion.com            doron.aronson@sun.com       ronald.white@cgi.ca





                                   SIGNATURES

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned, thereunto duly authorized.

                                      CGI GROUP INC.
                                          (Registrant)


Date June 26, 2001                        By /s/ Paule Dore
                                          Name:  Paule Dore
                                          Title:    Executive Vice President
                                                  and Chief Corporate Officer
                                                  and Secretary